Drug Trial Radar · NCT05442060
To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Aug 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Jul 27, 2022
Primary completion
Dec 31, 2025
Study completion May 31, 2026
Sponsor
- Lead sponsor
- OBI Pharma, IncIndustry
- Sponsor type
- Industry
- First posted
- Jul 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, active control, open-label, phase 2 trial. Erlotinib-treated NSCLC patients will be screened for Globo H, and only Globo H+ (H score ≥ 100) subjects are eligible for the study. Eligible subjects who have been treated with 3±1 months of first-line erlotinib and have achieved stable disease (SD) or partial response (PR) status will be randomized in the ratio of 1:1 to receive erlotinib alone or erlotinib plus OBI-833/OBI-821 therapy.
Conditions
- Non-small Cell Lung Cancer
Interventions
30 μg OBI-833/100 μg OBI-821Biological
Each subject in the OBI-833/OBI-821 + erlotinib combination arm will be treated with OBI-833/OBI-821 weekly for 4 doses (Weeks 1, 2, 3, 4), then every 2 weeks for 2 doses (Weeks 6, 8), then every 4 weeks for 4 doses (Weeks 12, 16, 20, 24), and then every 8 weeks until documented disease progression, intolerable adverse events (AEs)/toxicity, consent withdrawal, death, loss to follow-up, or up to 80 weeks from randomization.
Erlotinib (150 mg daily)Drug
All subjects in both arms will continue to receive erlotinib as the background therapy (150 mg daily).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival rated at one yearTime frame: One year
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Taichung Veterans General Hospital
Taichung, Taiwan · Recruiting
Taipei Veterans General Hospital
Taipei, Beitou District, Taiwan · Recruiting
National Taiwan University Cancer Center
Taipei, Da'an Dist., Taiwan · Recruiting
Linkou Chang Gung Memorial Hospital
Taoyuan, Guishan Dist., Taiwan · Recruiting
Tri-Service General Hospital
Taipei, Neihu District, Taiwan · Recruiting
Shuang Ho Hospital
New Taipei City, Zhonghe District, Taiwan · Recruiting
National Taiwan University Hospital
Taipei, Zhongzheng Dist., Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.